Skip to main content

Table 2 IQ in low risk randomisation groups (HDM versus intrathecal MTX)

From: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

  Number of patients Mean adjusted IQ*
(SD)
Difference in
means
(95% CI)
t-test
p-value
     HDM IT MTX    HDM IT MTX   
FSIQ       
   3 years    138 132 97.9
(16)
98.3
(16)
-0.4
(-4.4 : 3.5)
   0.8
   5 years    116 104 99.5
(15)
100.9
(18)
-1.4
(-5.8 : 3.0)
   0.5
VIQ       
   3 years    138 132 97.8
(15)
98.2
(15)
-0.4
(-4.0 : 3.3)
   0.8
   5 years    116 104 99.2
(14)
100.3
(17)
-1.1
(-5.2 : 3.0)
   0.6
PIQ       
   3 years    138 132 98.1
(17)
99.0
(17)
-1.0
(-5.0 : 3.1)
   0.6
   5 years    116 104 100.2
(15)
101.3
(19)
-1.1
(-5.7 : 3.4)
   0.6
  1. *IQ adjusted for test by subtracting:
  2. 7.15 from each WPPSI-R full IQ.
  3. 3.79 from each WPPSI-R verbal IQ.
  4. 8.74 from each WPPSI-R performance IQ.